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Phospholipases are produced from bacterial pathogens causing
very different diseases. One of the most intriguing aspects of
phospholipases is their potential to interfere with cellular signaling
cascades and to modulate the host–immune response. Here, we
investigated the role of the innate and acquired immune responses
elicited by Chlamydophila pneumoniae phospholipase D (CpPLD)
in the pathogenesis of atherosclerosis. We evaluated the cytokine
and chemokine production induced by CpPLD in healthy donors’
monocytes and in vivo activated T cells specific for CpPLD that in-
filtrate atherosclerotic lesions of patients with C. pneumoniae anti-
bodies. We also examined the helper function of CpPLD-specific
T cells for monocyte matrix metalloproteinase (MMP)-9 and tissue
factor (TF) production as well as the CpPLD-induced chemokine
expression by human venular endothelial cells (HUVECs).We report
here that CpPLD is a TLR4 agonist able to induce the expression of
IL-23, IL-6, IL-1β, TGF-β, and CCL-20 in monocytes, as well as CXCL-9,
CCL-20, CCL-4, CCL-2, ICAM-1, and VCAM-1 in HUVECs. Plaque-de-
rived T cells produce IL-17 in response to CpPLD. Moreover, CpPLD-
specific CD4+ T lymphocytes display helper function for monocyte
MMP-9 and TF production. CpPLD promotes Th17 cell migration
through the induction of chemokine secretion and adhesion mole-
cule expression on endothelial cells. These findings indicate that
CpPLD is able to drive the expression of IL-23, IL-6, IL-1β, TGF-β,
and CCL-20 by monocytes and to elicit a Th17 immune response
that plays a key role in the genesis of atherosclerosis.
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Host–pathogen interactions can lead to different types ofoutcomes depending on the kind of relationship that is
established when a microorganism enters his host cell. One of the
major factors involved in shaping “the picture” is the priming of
the immune system that can lead either to an effective clearance
of the pathogen or to an evasion of the immune response. In the
last decades, many efforts have been made to identify microbial
products that can have a key role in the pathogenesis of infections
by activating, modulating or down-regulating the host defenses.
Phospholipases (PLs) are a heterogeneous group of proteins with
enzymatic activity able to hydrolize phospholipids (1). They are
produced by both procaryotic and eukaryotic organisms and are
likely to be involved in membrane disruption occurring host cell
invasion. The realization that some fungal and bacterial toxins
were secreted PLs indicated that these molecules were, in fact,
virulence factors (2). Each enzyme is able to cleave a specific ester
bond on the phospholipid substrate, which forms the basis of their
nomenclature. PLD was first described in the early ’50s as a dis-
tinct enzyme with a specific phosphodiesterase activity leading to
the hydrolisis of phosphatidilcholine into phosphatidic acid (PA)
and choline (3). PA acts as a second messenger molecule and is
involved in key cellular processes such as membrane trafficking,
actin cytoskeleton remodelling, cell proliferation, and cell survival.
Chlamydophila pneumoniae is an obligate intracellular bacterium
present as free infectious, nonmetabolic elementary bodies (EB)
that transmit infection to susceptible eukaryotic cells such as
epithelial and endothelial cells, smooth muscle cells, and mac-
rophages. During its developmental cycle, C. pneumoniae differ-
entiates into metabolically active reticular bodies (RB) able to
replicate by binary fission and differentiate into EB, which cause
host cell lysis, thereby progressing the infectious cycle (4). Pro-
ductive infection is not the only possible outcome ofC. pneumoniae
interaction with host cells. Persistence due to nutritional depri-
vation, antibiotic treatment, or immune reaction leads to a chronic
or latent infection characterized by the presence of abnormal RB
that fail to mature (5). Some aspects of the developmental cycle of
C. pneumoniae suggest a direct implication of PLD in pathogen-
esis, specifically by affecting the regulation of lipid metabolism
and lipid exchange between C. pneumoniae and host cells. Over
the past two decades a strong link between chronic infection by
C. pneumoniae and the inflammatory process in atherosclerosis
has also been suggested (6). To characterize the activity of PLD
as virulence factor in C. pneumoniae infection, we have studied
the effect of C. pneumoniae PLD (CpPLD) (7) on the ability of
monocytes to prime the innate immune response and on CD4+
T cells to develop an adaptive immune response. In addition we
analyzed the possible role of CpPLD on endothelial cell (EC)
activation. We have found that CpPLD-specific T cells were
present within the lesion and they exhibited a Th17 cytokine
pattern. Moreover, CpPLD-specific T cells were able to strongly
promote the production of both tissue factor (TF) and metal-
loproteinase 9 (MMP-9) involved in plaque rupture and athero-
trombotic events. We demonstrated that CpPLD was able to
activate monocytes by binding Toll-like receptor 4 (TLR4),
leading to the production of IL-23, IL-6, IL-1β, TGF-β, and CCL-
20, molecules critical for the generation, differentiation, and
maintenance of Th17 cells. Furthermore, CpPLD was able to
elicit the up-regulation of the expression of several chemokines
and adhesion molecules such as CXCL-9, CCL-20, CCL-4, CCL-
2, ICAM-1, and VCAM-1 in human venular endothelial cells
(HUVECs). These results demonstrate that CpPLD is able to
drive Th17 inflammation within the atherosclerotic plaque and
suggest that PLD-activated Th17 cells play a crucial role in ath-
erosclerosis, plaque rupture, and atherothrombotic events.
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Results
PLD Drives IL-17 and IL-21 Secretion from Th Cells Derived from
Atherosclerotic Plaques. T-cell lines from atherosclerotic plaques
were cultured and analyzed for IL-17 and IL-21 production in
culture supernatants. After 72 h of stimulation with immobilized
anti-CD3 mAb, they produced high levels of IL-17 and IL-21 (Fig.
1A). We next examined whether carotid plaque-derived T cells
from patients with atherosclerotic arteriopathy produced IL-17.
Atherosclerotic plaque-derived anti-CD3 mAb-induced T-cell
lines were expanded from seven Cp-positive (Cp-pos) and from five
Cp-negative (Cp-neg) patients as control by addition of human
recombinant IL-2 (hrIL-2) every 3 d. At day 15, T-cell blasts of
each plaque T-cell line were stimulated with CpPLD, tetanus
toxoid (TT), or purified protein derivative (PPD) in the presence of
autologous antigen presenting cells (APCs) for 48 h in ELISPOT
microplates coated with anti–IL-17 antibody. At the end of the
culture period, the number of IL-17 spot-forming cells (SFCs) were
counted (Fig. 1B). A significant proportion of all plaque-derived T-
cell lines, under MHC restricted conditions, reacted specifically to
CpPLD by producing IL-17 in a dose-dependent fashion (Fig. 1C).
PLD-Specific T-Cell Clones Infiltrating the Atherosclerotic Lesions of
C. pneumoniae-Positive Patients Display a Th17 Phenotype. In vivo-
activated plaque-infiltrating T cells were expanded in vitro in
hrIL-2–conditioned medium, subsequently cloned and studied
for their phenotypic and functional profile (8).
A total number of 223 CD4+ and 49 CD8+ T-cell clones were
obtained from plaques of the seven Cp-pos patients. For each
patient, CD4+ and CD8+ plaque-derived T-cell clones were as-
sayed for proliferation in response to medium, C. pneumoniae EB
(CpEB), CpPLD, H. pylori lysate (NCTC11637 strain; 10 μg/mL)
and PHA.None of the CD8+T-cell clones showed proliferation to
CpPLD, CpEB, and to H. pylori lysate. In contrast, 44 (20%) and
13 (6%) of the 223 CD4+ T-cell clones generated from plaque-
infiltrating T cells proliferated significantly to CpEB and to
CpPLD, respectively, but not to the H. pylori lysate (Fig. 2 and
Tables S1 and S2). Upon antigen stimulation with CpPLD, all
of the 13 PLD-specific T-cell clones secreted IL-17. Among the
IL-17–secreting PLD-specific T-cell clones, five were producing
both IL-17 and IFN-γ (Fig. S1A). None of these clones where able
to produce IL-4, whereas all clones were able to produce IL-21 in
response to antigen stimulation (Fig. S1B). A total number of 165
CD4+ and 32 CD8+ T-cell clones were obtained from plaques of
five Cp-neg patients. None of these clones proliferated to either
C. pneumoniae or H. pylori (Table S1).
PLD-Specific Plaque-Infiltrating T Cells Promote TF and MMP-9
Production by Monocytes. Studies of human vessels suggest that
gelatinases in general are highly expressed in fatty streaks and
atherosclerotic plaques compared with normal regions of the
vessel (9). Because plaque rupture and thrombosis are notable
complications of atherosclerosis, we asked whether plaque-in-
filtrating PLD-specific T cells had the potential to express helper
function for TF and MMP-9 production by monocytes. Antigen-
stimulated PLD-specific T-cell clones from plaques were cocul-
tured with autologous monocytes, and the levels of TF and
MMP-9 were measured. Antigen stimulation resulted in the ex-
pression of substantial help for TF production by monocytes
(Fig. 3A). Likewise monocytes incubated with antigen-stimulated
CpPLD-specific T-cell clones were able to produce significant
levels of MMP-9 (Fig. 3B).
PLD Activates Monocytes to Release Cytokines Essential for the
Differentiation of Th17 Cells. IL-23 is a heterodimeric cytokine
sharing the p40 subunit with IL-12 and having a distinct p19
subunit (10). CpPLD was able to induce the expression of both
IL-12p40 and IL-23p19 in monocytes (Fig. 4 A and B). The
kinetics of expression of the two subunits were consistent with
those of protein accumulation in culture supernatants (Fig. 4C).
IL-23 is an essential survival factor for Th17 cells, because
these cells are not present in mice lacking IL-23 (11). Recent
Fig. 1. CpPLD-driven IL-17 secretion by atherosclerotic plaque Th cells from
patients with atherosclerosis. (A) Release of IL-17 and IL-21 from fresh ath-
erosclerotic plaque Th cells after 72 h of stimulation with immobilized anti-
CD3 monoclonal antibody (mAb). (B) Numbers of IL-17 SFCs after stimulation
of fresh atherosclerotic plaque Th cells with CpPLD, OMP-2, TT, or PPD.
Atherosclerotic plaque-derived anti-CD3 mAb-induced T-cell lines were ex-
panded from Cp-pos (gray bars) and from Cp-neg (white bars) patients as
control by addition of hrIL-2, every 3 d. At day 15, T-cell blasts from each line
were stimulated for 48 h with CpPLD, OMP-2, TT, or PPD in the presence of
irradiated autologous APCs in enzyme-linked immunospot microplates
coated with anti–IL-17 antibody. IL-17 spot-forming cells were then counted
by using an automated reader. After specific stimulation with CpPLD, a sig-
nificant proportion of Cp-pos atherosclerotic plaque-derived Th cells pro-
duced IL-17. (C) Dose–response effect of graded concentrations of CpPLD
antigen on the numbers of IL-17 spot-forming cells. Values are the mean ± SD
number of spot-forming cells per 105 cultured cells over background levels.









findings suggest, however, that IL-23 is not required during the
early differentiation of Th17 cells, because IL-23R is not
expressed on naïve T cells, but would serve to expand previously
differentiated Th17 cells (12). Other factors such as IL-6, IL-21,
and TGF-β involved in the initial differentiation of Th17 were
identified (13). Accordingly, the messenger RNA (mRNA) and
protein amounts of these cytokines were determined after
CpPLD stimulation of monocytes. Increased levels of IL-6
mRNA were found, with a peak production after 5 h of stimu-
lation, and high levels of IL-6 were measured in culture super-
natants (Fig. 5 A and B). CpPLD also induced high expression of
TGF-β mRNA, which started to increase and peaked after 1 h
from CpPLD addition, leading to the accumulation of the pro-
tein in the supernatant (Fig. 5 C and D). IL-1β mRNA was found
to significantly increase after 5 h following CpPLD stimulus and
peaked after 24 h from CpPLD addition along with the protein
production in the supernatants (Fig. 5 E and F). Furthermore,
CpPLD was able to stimulate CCL-20 mRNA production, which
started to increase and peaked after 5 h from CpPLD addition
and was still substantial after 24 h from stimulation with high
levels of protein production detectable in the supernatants
(Fig. 5 G and H). These findings indicate that CpPLD, acting on
monocytes, contributes to create a cytokine milieu enriched in
IL-6, TGF-β, IL-1β, and IL-23 with a strong potential of driving
the T-cell differentiation toward the Th17 subset (Fig. S3). In-
deed, the up-regulation of CCL-20 mRNA production is a sig-
nificant hallmark for the presence and maintenance of CCR6-
positive Th17 cells through their positive chemotactic stimulus.
IL-23 Secretion Follows PLD Binding to TLR4. To investigate the
mechanism of CpPLD monocyte activation, we evaluated the
possibility that CpPLD activates a TLR-mediated signaling. Con-
sidering that bacterial proteins preferentially activate monocytes
and dendritic cells via TLR2 or TLR4, we used human embryonic
kidney (HEK) 293 cells transfected with plasmids encoding either
of them. HEK293 cell lines lack expression of endogenous TLRs,
although their TLR signaling machinery is fully functional. The
common pathway leading to NF-κB activation requires phos-
phorylation and degradation of the cytosolic inhibitor of NF-κB,
IκB-α. The engagement of a specific TLR, expressed on HEK293,
was monitored by evaluating the phosphorylation of IκB-α after
exposure to CpPLD. As shown in Figs. S4 and S5, phosphorylation
of IκB-α was observed in cells expressing TLR4, but not in those
expressing TLR2. In addition, an anti-TLR4 blocking antibody
abrogated the PLD induction of IL-23 (Fig. S4).
PLD Promotes Th17 Cells Migration Through the Induction of Chemokine
Production and Adhesion Molecule Expression on HUVEC. Chemo-
kines and adhesion molecules produced by ECs are important in
driving T-cell trafficking. Given that CCL-4, CCL-2, CCL-20,
and CXCL-9 acting on CCR5, CCR2, CCR6, and CXCR3, re-
spectively, are able to chemoattract Th17 cells (14), we inves-
tigated whether CpPLD was able to induce mRNA expression
and protein production of different chemokines and adhesion
molecules in HUVECs. As shown in Fig. S6, upon stimulation
with CpPLD HUVEC were able to produce significant levels of
CCL-4, CCL-2, CCL-20, CXCL9, sICAM-1, and sVCAM-1.
Discussion
One of the most intriguing aspects of PLs as virulence factors is
their potential ability to modulate host–immune response. Little
is known about CpPLD, and additional data are needed to
provide an understanding of the common biological processes
required for infection and survival of this pathogen in mamma-
lian cells. In this study, we investigated the type of innate and
acquired immune responses evoked by CpPLD in Cp-pos
patients with atherosclerosis. A serological response to CpPLD
has been described in the sera of patients with acute coronary
syndromes infected by C. pneumoniae but not in those of healthy
Fig. 2. Antigen specificity of plaque-infiltrating T-cell clones. Th clones
were tested for proliferation to (CpEB), recombinant CpPLD, and H. pylori
lysate in the presence of irradiated autologous APCs.
Fig. 3. CpPLD-specific T cells induce TF and MMP-9 production by autologus monocytes. To assess their ability to induce TF and MMP-9 production by
autologus monocytes, CpPLD-specific Th clones were cocultured with autologous monocytes in the presence of medium or CpPLD. TF (A) and MMP-9 (B)
production by monocytes were assessed by ELISA. The results shown represent the TF and MMP9 levels induced by T-cell clones over the TF and MMP9
production in cultures of monocytes alone, respectively.
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subjects and anti-Cp antibody titers were higher in subjects with
both IgG and IgA than in those with IgG only (15). T cells play
an important role in the genesis of atherosclerosis that has been
defined a Th1-driven immunopathology (16, 17), and we have
demonstrated that Th1 cells, producing high levels of IFN-γ, are
crucial for the development of the disease (18, 19). Given that
atherosclerosis can occur and progress even in IFN-γ–deficient
mice or its receptor, although with a lower lesion burden (20),
other Th cells and factors are presumably involved in the genesis
of the atheroma. Recently, a third subset of effector Th cells,
namely Th17, has been discovered (21). Th17 cells are potent
inducers of tissue inflammation and have been associated with
the pathogenesis of many experimental autoimmune diseases
and human inflammatory conditions (22, 23). In the lymphocytic
infiltrates of human atherosclerotic plaques, we have found the
presence of in vivo-activated plaque-infiltrating T cells able to
produce IL-17 and IL-21 in response to CpPLD. Among the
clonal progeny of T cells infiltrating the lesions, we demonstrated
the presence of CpPLD-specific T cells able to secrete IL-17. A
significant number (38%) of IL-17–producing T cells are also
IFN-γ producers. This finding is in agreement with a previous
report that demonstrated the concomitant production of IL-17
and IFN-γ by human coronary artery-infiltrating T cells (24, 25).
Plaque rupture and thrombosis are notable complications of
atherosclerosis (26). The CpPLD-specific T-cell clones revealed
their ability to induce macrophage production of TF upon an-
tigen stimulation. Several studies have provided a clear in-
dication of an important role of MMPs in atherothrombosis (9).
It has been suggested that the myocardial or cerebral ischemic
complications may, in fact, depend more on the plaque compo-
sition than on the degree of stenosis. The composition of the
extracellular matrix may affect plaque progression and also be
a key determinant of plaque vulnerability (27). The infiltration of
inflammatory cells into the atherosclerotic lesion results in
a major increase of MMP activity (9). It is of note that CpPLD-
specific T-cell clones were able to stimulate the production of
MMP-9 from the monocytes of patients. Th17 cells were shown
to play a key role in experimental mouse models of atheroscle-
rosis; IL-17 is proatherogenic in both diet-induced atheroma
development and C. pneumoniae infection-mediated accelera-
tion of atherosclerotic lesions in the presence of high fat diet
(HFD) in mice (28). In fact, in IL-17−/− mice fed with HFD and
infected with C. pneumoniae, the aortic lesion size and lipid
composition as well as macrophage accumulation in the plaques
were significantly diminished, and the progression of the process
was significantly reduced compared with WT mice. C. pneumo-
niae was known to induce IL-17 (25), but the nature of the
bacterial molecule(s) able to stimulate Th17 development was
not known. We have demonstrated that CpPLD was able to
activate both the mRNA expression and the production of IL-23,
IL-6, IL-1β, and TGF-β by monocytes. All these cytokines have
proved to be crucial for the induction of Th17 cell responses
(11). These findings do not exclude the possibility that additional
bacterial factors contribute to the generation of the Th17 cell
response found in the atherosclerotic lesion. Furthermore,
CpPLD was also able to induce the up-regulation of both mRNA
and protein production of CCL-20 in monocytes, a ligand for
CCR6 expressed by activated Th17 cells (29). Th17 cells are
highly heterogeneous in terms of trafficking receptors. Many of
these receptors are involved in T-cell migration into inflamed
tissue sites; therefore, the receptor expression profile of Th17
cells is consistent with their inflammatory activities in non-
lymphoid tissues (14). We also demonstrated that CpPLD is
a TLR-4 agonist that was able to activate NF-κB in TLR4-
transfected but not in TLR2-transfected HEK 293 cells. The
involvement of the TLR4 receptor in the activation of monocytes
by CpPLD was further supported by the abrogation of CpPLD-
induced IL-23 expression by a specific anti-TLR4 blocking an-
tibody. Current evidence indicates that CCL-4, CCL-2, CCL-20,
CXCL-9, VCAM-1, and ICAM-1 are important in the genesis of
atherosclerosis (30) and that CCL2 and CCL20 are relevant in
promoting Th17 cell migration (31–33). We have investigated
the potential role of CpPLD on the expression of different
molecules by EC. Our data obtained in HUVECs demonstrated
that CpPLD was able to induce an increased expression of dif-
ferent chemokines such as CXCL-9, CCL-20, CCL-4, and CCL-
2. Interestingly, this chemokine profile suggests that Th17 cells
selectively migrate within the atherosclerotic lesion upon CpPLD
stimulation. Such a chemokine pattern can also account for the
presence of CpPLD-specific T cells able to produce both IL-17
and IFN-γ, which share a chemokine receptor phenotype asso-
ciated with both Th17 and Th1 cells (14, 25). Leukocyte inter-
actions with vascular endothelium at sites of inflammation can be
dynamically regulated by activation-dependent adhesion mole-
cules. We investigated the role of CpPLD in the expression of
ECs adhesion molecules involved in the adhesion and diapedesis
of leukocytes. Our results obtained on HUVECs demonstrated
that CpPLD was able to up-regulate the mRNA expression of
sICAM-1 and sVCAM-1, thus promoting tissue inflammation
within the plaque. Overall, our findings support the concept that
a crucial component of atherosclerosis is represented by T-cell–
mediated immunity and that chronic Th response against
Fig. 4. Kinetics of the synthesis and production of interleukin-23 (IL-23) by
freshly isolated monocytes stimulated with CpPLD. Levels of IL-12p40 (A) and
IL-23p19 (B) cytokine mRNA in monocytes from healthy donors were de-
termined at the indicated time points after CpPLD stimulation, by quanti-
tative real-time PCR analysis. Shown are representative results from one of
four experiments conducted with different cell preparations. Values are the
mean and SD arbitrary units (AU). Levels of IL-23 protein in monocytes from
healthy donors were determined at the indicated time points after CpPLD
stimulation by ELISA of culture supernatants from the same cells that had
been harvested for mRNA evaluation (C). The kinetics of production were
comparable among the different experiments, whereas the amounts pro-
duced varied among the different donors. Values are the mean ± SD of four
independent experiments by using triplicate samples.









C. pneumoniae plays an important role in the genesis of ather-
oma. Specifically, we have demonstrated that CpPLD is able to
elicit a Th17 immune response within the plaque by activating
ECs and macrophages to express and secrete a wide variety of
chemokines and cytokines. Within CpPLD-specific IL-17–pro-
ducing Th cells, the majority were polarized Th17 cells, whereas
others were able to produce both IFN-γ and IL-17. Thus, it is
possible to speculate that Th17 and Th1 cells comigrate to the
inflamed tissue and cooperate to the ongoing inflammatory
process within the atherosclerotic lesion (21). Our results dem-
onstrate that CpPLD is a major C. pneumoniae factor able to
drive Th17 inflammatory process in atherosclerosis and suggest
that Th17 cell pathway and CpPLD may represent unique ther-
apeutic targets for the prevention and treatment of the disease.
Materials and Methods
Reagents. hrIL-2, TT, and PPD were provided by Chiron. Recombinant CpPLD
was produced as an endotoxin-free material, as described (7). Endotoxin
levels were determined in all of the CpPLD preparations used in the study by
the limulus amebocyte lysate assay (BioWhittaker Cambrex), and they were
between 0.05 and 0.1 endotoxin unit per microgram of protein.
Carotid Artery T-Cell Lines from Atherosclerotic Patients. Upon the approval of
the local Ethical Committee, carotid plaques were obtained by endoarter-
ectomy from seven patients (four males and three females, mean age 65;
range 58–70 y) with atherosclerotic arteriopathy. Patients (Cp-pos) were se-
lected on the basis of detectable serum levels of anti-C. pneumoniae anti-
bodies (Eurospital). Fresh plaque-derived T cells (1 × 105) were stimulated by
immobilized anti-CD3 (OKT3) monoclonal antibody (5 μg/mL) in round-bot-
tom microwell plates (30). After 72 h of stimulation, supernatants were col-
lected and assayed for IL-17 and IL-21 by ELISA (R&D Systems and eBioscience,
respectively). At day 15, T-cell blasts of each Cp-pos plaque T-cell line were
stimulated with CpPLD (10 μg/mL), outer membrane protein (OMP)-2 (10 μg/
mL), TT (0.5 μg/mL), or PPD (10 μg/mL) in the presence of autologous APCs for
48 h in ELISPOT microplates coated with anti–IL-17 antibody (eBioscience).
The antigen-specific T-cell response was also evaluated in five patients
without anti-C. pneumoniae antibody (Cp-neg), used as control. At the end of
culture period, the number of IL-17 SFCs were counted as described (34).
Generation of T-Cell Clones from Atherosclerotic Plaques. Plaque-derived T
cells were cloned under limiting dilution, and clones were screened for re-
sponsiveness to C. pneumoniae sonicated EB (104 inclusion forming units per
mL), CpPLD (10 μg/mL), or H. pylori lysate (10 μg/mL) as described (8).
Assessment of T-Cell Clones Cytokine Profile. To assess their cytokine pro-
duction, T-cell blasts (106 cells per mL) of each clone were stimulated for 36 h
with phorbol-12-myristate 13-acetate (PMA; 10 ng/mL) in wells coated with
anti-CD3 mAb, as reported (35). At the end of culture period, duplicate
samples of each supernatant were assayed for IFN-γ, IL-4 (BioSource In-
ternational), IL-17 (R&D Systems), and IL-21 (eBioscience).
Assay for T-Cell Clone Helper Function for Monocyte TF and MMP9 Production.
T-cell blasts of C. pneumoniae-specific clones (8 × 105/mL) were cocultured
for 16 h with autologous monocytes (4 × 105/mL) in the presence of medium
or antigen CpPLD (10 μg/mL). At the end of the culture period, TF was
quantitated as reported (18). To assess their ability to induce MMP-9 activity
by monocytes, PLD-specific T-cell clones were cocultured with autologous
monocytes in the presence of medium or CpPLD antigen (10 μg/mL). The
MMP-9 activity was measured by using the SensoLyte MMP-9 ELISA Kit
(Anaspec) according to the manufacturer’s instructions.
Preparation of Monocytes and HUVEC. Human monocytes and HUVECs were
prepared as described (36, 37). Monocytes were cultured in RPMI 1640 10%
FCS in the presence of CpPLD (5μg/mL) or PBS, as control.
Real-Time PCR Analysis. Total RNA was isolated by using TRIzol solution
(Invitrogen) according to the manufacturer’s instructions. RNA was reverse-
transcribed and amplified, using Light Cycler (Roche), with the appropriate
primers for GAPDH, IL23p19, IL12p40, IL6, IL1β, CCL-20, CCL4, CCL2, CXCL9,
VCAM, and ICAM, as described (34).
Detection of Cytokines and Chemokines in Culture Supernatants. Culture
supernatants were collected, and the amount of IL-23, IL-6, IL-1β, CCL-4,
Fig. 5. Kinetics of the synthesis and production of IL-6, TGF-β, IL-1β, and
CCL-20 by freshly isolated monocytes stimulated with CpPLD. (A, C, E, and G)
Levels of IL-6, TGF-β IL-1β, and CCL-20 mRNAs were determined by quanti-
tative real-time PCR at the indicated time points after CpPLD stimulation.
AU, arbitrary units. (B, D, F, and H) Levels of IL-6, IL-1β, and CCL-20 proteins
were determined by ELISA at the indicated time points after CpPLD stimu-
lation. TGF-β content was measured by using CCL64 bioassay. Culture
supernatants from the same monocytes that were harvested for mRNA
evaluation were used for these analyses. Values are the mean and SD of four
independent experiments by using triplicate samples.
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CCL-2, CCL-20, CXCL-9, CCL-20, VCAM-1, and ICAM-1 was quantified by
ELISA (eBioscience, R&D Systems, and RayBiotech) according to the manu-
facturer’s instructions. The inhibition of 3H-thymidine incorporation into DNA of
CCL64 mink lung epithelial cells was used as a sensitive bioassay for TGF-β (38).
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Fig. S1. C. pneumoniae antigen-induced cytokine production by plaque-infiltrating T-cell clones. C. pneumoniae-specific Th clones were stimulated with the
appropriate antigen, and IL-17 and IFN-γ (A) and IL-21 and IL-4 (B) production was measured in culture supernatants. In unstimulated cultures, levels of IL-17,
IFN-γ, IL-21, and IL-4 were consistently <20 pg/mL.
Fig. S2. IL-17 and IFN-γ intracellular cytokine staining of plaque-infiltrating T cells. Cells were stained for surface and intracellular markers with the following
mAbs for flow cytometry: anti–CD4-PerCP, anti–IL-17-PE, and anti–IFN-γ-FITC (Becton Dickinson). Samples were stimulated with 25 ng/mL PMA plus 1 μg/mL
ionomycin in the presence of brefeldin A (1 μg/mL). Dot plots expression of IL-17 and IFN-γ on CD4+ T cells of three representative T-cell lines are shown.
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Fig. S3. Effect of CpPLD-cultured monocytes supernantants on Th17 cell differentiation. Enriched CD4+ T cells were purified by using the StemSep Human
T-cell enrichment kit (Voden Medical Instruments) were activated by anti-CD3 mAb (OKT3) with or without CpPLD-cultured monocytes supernatants
(CpPLDsup); with IL-23 plus IL-1β; or with CpPLDsup plus blocking anti–IL-23 and anti–IL-1β. Recombinant human IL-2 was added to the cultures on days 4 and 7.
After 10 d, cells were washed and restimulated for 48 h in enzyme-linked immunospot microplates coated with anti–IL-17 mAb. IL-17 spot-forming cells were
then counted by using an automated reader. Values are the mean ± SD number of spot-forming cells (SFCs) per 105 cultured cells over background levels.
Fig. S4. Engagement of Toll-like receptor 4 (TLR-4) by CpPLD and its involvement in the production of interleukin-23 (IL-23). (A) HEK 293 cells expressing
either TLR-2 or TLR-4 were incubated with CpPLD. As positive controls, Listeria monocytogenes was used for TLR-2–expressing cells, and lipopolysaccharide
(LPS) was used for TLR-4–expressing cells. Mock cells represent the negative control. Cell lysates were subjected to SDS/PAGE and immunoblotted with anti–
phospho-IκB-α antibodies. Total α-actin antibody was used as a control for equal loading. (B) Cells were either not preincubated or were preincubated for 2 h
with 20 μg/mL of an anti–TLR-4 blocking antibody and then exposed to CpPLD. After 12-h culture, supernatants were collected and analyzed by ELISA for levels
of the secreted IL-23. The bar on the left shows IL-23 secretion after CpPLD stimulation, and the bar on the right shows IL-23 secretion after a 2-h preincubation
with 20 μg/mL of an anti–TLR-4 blocking antibody followed by stimulation with CpPLD. Values in B are the mean ± SD of four independent experiments by
using triplicate samples.
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Fig. S5. Dose-dependent effect of CpPLD on TLR4 activation and timecourse of IL-23 monocyte production after CpPLD stimulation. (A) Activation of NF-κB in
HEK 293 cells transfected with plasmid-encoding human TLR4. Parallel culture samples of hTLR4-transfected HEK 293 cells were stimulated with graded
concentrations of CpPLD (squares) or LPS (diamonds). The NF-κB activation in each sample was quantified as OD values after 24 h of stimulation. Results of
a representative experiment are reported. (B) Production of IL-23 after monocyte stimulation with CpPLD (gray bars) (10 μg/mL) or LPS (white bars) (1 μg/mL) at
the indicated time points. Shown are representative results from one of four independent experiments.
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Fig. S6. Kinetics of the synthesis and production of CCL-4, CCL-2, CCL-20, CXCL-9, VCAM-1, and ICAM-1 by HUVEC stimulated with CpPLD. (A, C, E, G, I, andM)
Levels of CCL-4, CCL-2, CCL-20, CXCL-9, VCAM-1, and ICAM-1 mRNAs were determined by quantitative real-time PCR at the indicated time points after CpPLD
stimulation. AU, arbitrary units. (B, D, F, H, L, and N) Levels of CCL-4, CCL-2, CCL-20, CXCL-9, sVCAM-1, and sICAM-1 proteins were determined by ELISA at the
indicated time points after CpPLD stimulation. Values are the mean ± SD of four independent experiments using triplicate samples.
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Table S1. Antigen specificity of T-cell clones isolated from atherosclerotic plaques
Patients and source of T cells
Total no. of CD4+ T-cell
clones obtained
No. of clones reactive to: (%)
C. pneumoniae H. pylori
C. pneumoniae positive patients
AM 30 5 (16) 0
BJ 43 9 (21) 0
ST 28 4 (14) 0
HE 34 7 (20) 0
TL 27 6 (22) 0
GB 35 8 (23) 0
PF 26 5 (19) 0
C. pneumoniae negative patients
FB 34 0 0
GM 41 0 0
BB 35 0 0
RG 29 0 0
AC 26 0 0
T-cell clones were cocultured with medium alone or C. pneumoniae sonicated elementary bodies (104 inclusion forming units
per mL), or H. pylori lysate (10 μg/mL) in the presence of irradiated autologous APCs. Proliferative responses were measured
after 3 d.
Table S2. Effect of addition in culture of anti-DR or anti-DQ
monoclonal antibodies on the proliferative response to CpPLD
by atherosclerotic plaque T-cell clones reactive to CpPLD
Proliferative response in the presence of
T-cell clones Isotype control Anti-DR Anti-DQ
1. AM 3 83 ± 8 1.4 ± 0.2 82 ± 7
2. BJ 4 32 ± 5 0.8 ± 0.1 34 ± 4
3. ST 2 51 ± 9 1.2 ± 0.3 50 ± 6
4. HE 9 91 ± 6 1.4 ± 0.2 89 ± 5
5. TL 7 34 ± 7 1.5 ± 0.3 33 ± 4
T-cell clones were stimulated by CpPLD (10 μg/mL) in the presence of
irradiated autologous APCs treated with anti–HLA-DR (clone G46-6) or
anti–HLA-DQ (clone TU169) (5 μg/mL final concentration) mAbs to know
the MHC restriction elements. Anti–HLA-DR resulted consistently in virtual
abrogation of the proliferative response by T-cell clones to CpPLD, whereas
anti–HLA-DQ was unable to affect CpPLD-induced T-cell clone proliferation.
Proliferative response (MI) were measured after 3 d. Values are MI ± SD.
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